The US Food and Drug Administration (FDA) has approved Roche’s cobas epidermal growth factor receptor (EGFR) mutation test v2 as a companion diagnostic for non-small cell lung cancer (NSCLC) therapies.

The test features expanded mutation coverage of the EGFR gene in DNA derived from tumor tissue. It can be used to select eligible NSCLC patients who have a T790M mutation to treat with AstraZeneca‘s Tagrisso (osimertinib) lung cancer therapy.

It can also be used for eligible NSCLC patients with exon 19 deletions or L858R mutations for treatment with Tarceva (erlotinib), a once-daily, oral non-chemotherapy medicine for advanced or metastatic NSCLC.

"The test features expanded mutation coverage of the EGFR gene in DNA derived from tumor tissue."

Roche developed the cobas EGFR mutation test v2 based on the cobas EGFR mutation test, which is available in the US.

It finds 42 EGFR mutations in exons 18-21, including L858R, exon 19 deletions, and T790M.

Roche Molecular Diagnostics head Paul Brown said: "Today’s FDA approval and companion diagnostic designation for the cobas EGFR mutation test v2 is an important advancement in the testing of lung cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"With this test, physicians can identify those patients whose tumor harbors an EGFR mutation and therefore are eligible for important targeted therapies for first-line and subsequent lines of treatment, thus expanding their therapy options."

Roche said the cobas EGFR mutation test v2 is aimed to be used as an aid in finding NSCLC patients for whom treatment with Tarceva in first-line therapy, and Tagrisso in second and successive lines of therapy, may be effective.

Image: cobas IMPACT, a chip-based immunological multimarker assay (biomarkers). Photo: courtesy of F Hoffmann-La Roche.